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Article focus
  to investigate a new commercially 
available bone substitute that elutes 
antibiotics, with an initial high local 
release and a sustainable antibiotic level 
to effectively prevent recurrence of 
infection.
  to compare the elution of gentamicin 
from a synthetic bone substitute in vitro 
with elution and efficacy in clinical 
applications.
Key messages
  the in vitro antibiotic elution test method 
presented in this study predicts the local 
antibiotic elution in vivo and makes it a 
reliable tool in the research and develop-
ment of future antibiotic-eluting bone-
regenerating materials.
  local elution of antibiotics from a regen-
erating bone substitute effectively pre-
vents recurrence of infection and supports 
bone healing.
pharmacokinetics of gentamicin eluted 
from a regenerating bone graft substitute
in vitro aNd cliNical ReleaSe StudieS
Objectives
Deep bone and joint infections (DBJI) are directly intertwined with health, demographic 
change towards an elderly population, and wellbeing.
The elderly human population is more prone to acquire infections, and the consequences 
such as pain, reduced quality of life, morbidity, absence from work and premature retire-
ment due to disability place significant burdens on already strained healthcare systems and 
societal budgets.
DBJIs are less responsive to systemic antibiotics because of poor vascular perfusion in 
necrotic bone, large bone defects and persistent biofilm-based infection. emerging bacte-
rial resistance poses a major threat and new innovative treatment modalities are urgently 
needed to curb its current trajectory.
Materials and Methods
We present a new biphasic ceramic bone substitute consisting of hydroxyapatite and calcium 
sulphate for local antibiotic delivery in combination with bone regeneration. Gentamicin 
release was measured in four setups: 1) in vitro elution in Ringer’s solution; 2) local elution 
in patients treated for trochanteric hip fractures or uncemented hip revisions; 3) local elu-
tion in patients treated with a bone tumour resection; and 4) local elution in patients treated 
surgically for chronic corticomedullary osteomyelitis.
Results
The release pattern in vitro was comparable with the obtained release in the patient studies. no 
recurrence was detected in the osteomyelitis group at latest follow-up (minimum 1.5 years).
Conclusions
This new biphasic bone substitute containing antibiotics provides safe prevention of bone 
infections in a range of clinical situations. The in vitro test method predicts the in vivo per-
formance and makes it a reliable tool in the development of future antibiotic-eluting bone-
regenerating materials.
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Strengths and limitations
  Strengths: this study compares in vitro data with 
in vivo performance in three different clinical settings.
  limitations: the local concentration of gentamicin 
was not measured in the osteomyelitis patients, and 
the detection limit of the equipment measuring the 
gentamicin concentrations in the drainage, serum 
and urine of studied patients prevented measure-
ments of concentrations below 0.2 mg/l.
Introduction
local delivery of antibiotics has been shown to be suc-
cessful in treating active infections1-3 as well as for pro-
phylactic use.4 many different carriers have been used 
with different results5 and the ideal delivery material is yet 
to be found.
the first local antibacterial treatments were performed 
by Joseph lister and published in the Lancet in 1867.6 
lister used carbolic acid and other local antiseptics in 
open fracture treatments, in addition to aseptic covering, 
thereby significantly decreasing the morbidity caused by 
infection.
deep bone and joint infections (dBJi) still constitute a 
significant and costly societal burden globally. Whether 
caused by trauma, tumour surgery or joint replacement, 
dBJis may require repeated invasive revision surgery and 
extensive systemic antimicrobial treatment that can last 
for years. in addition to potentially serious side effects, 
aggressive long-term systemic antibiotic treatments con-
tribute to emerging bacterial resistance. although major 
advances in aseptic and antiseptic routines have been 
achieved, approximately 30% of open fractures and 5% 
of closed fractures treated with fixation devices still 
become infected.5,7
the ongoing demographic changes in an ageing 
world have an impact on health care with 2.5 million arti-
ficial joints being inserted yearly.8,9 the most feared early 
complication is deep prosthetic joint infection, which 
occurs in 1% to 2% of patients who undergo joint replace-
ment.10 as the typical patient tends to be an older indi-
vidual with substantial comorbidity, an infection often 
results in prolonged and repeated surgeries, secondary 
complications, chronic morbidity, and even mortality 
related to the systemic antibiotic treatment and immobi-
lisation.10,11 this patient group is especially susceptible to 
highly contagious and potentially life-threatening 
Clostridium difficile enteritis caused by long-term systemic 
treatment using the few remaining effective antibiotics. 
Clostridium enteritis, the leading cause of hospital-
acquired diarrhoea, has a mortality rate ranging from 
60% to 83%, and 40 000 deaths are reported yearly in the 
uS alone.12
From a cost perspective, the increased direct cost for a 
patient with a prosthetic joint infection is five to seven 
times higher than for a primary procedure, corresponding 
to an additional € 40 000 per patient.13 Substantial suffer-
ing could be prevented and resources saved if more effi-
cient treatment and prevention existed.
local antibiotic delivery is an attractive option if it can 
be shown that it can be delivered safely with no systemic 
adverse effects. it may act synergistically with systemic 
antimicrobial therapy and may be better able to perfuse 
poorly vascularised bone in chronic osteomyelitis. 
carriers for local antibiotic treatment currently or previ-
ously in use may be divided into six categories: non- 
biodegradable polymers; bone grafts; bone graft 
substitutes; collagen; gels; and aqueous solutions. Non-
biodegradable carriers are mainly represented by polym-
ethyl methacrylate (pmma), usually in the form of blocks 
or beads. the antibiotic release from pmma occurs from 
the surface by diffusion, and is therefore controlled by the 
surface area and the concentration gradient between the 
material surface and the surrounding tissue.14 this results 
in a high local level of antibiotics for the first one to three 
days post-operatively, followed by a sustained slow 
release that steadily decreases over weeks.15 elution has 
been reported up to five years after pmma bead implan-
tation.16,17 the long elution time of low levels of antibiot-
ics is a major disadvantage, as it may cause bacterial 
resistance when the antibiotic release falls below thera-
peutic levels. at this point, the pmma will act as a foreign 
body and will be a source of recurrent infection due to 
colonisation of the surface and biofilm formation.17,18
a biodegradable carrier such as a bone graft substi-
tute, collagen or a gel would theoretically decrease the 
risk of recurrence of infection and generation of resist-
ance since it resorbs quickly and completely and all the 
antibiotic is released.5 However, the release from this 
group of carriers has repeatedly been reported as very 
fast and at a relatively uncontrolled rate.19
morselised bone grafts, with the addition of antibiotics 
in powder form or soaked in an antibiotic solution,20 have 
been used as local antibiotic carriers since 1984.19 Good 
results have been achieved21-25 with up to a 90% success 
rate in hip revisions,22 and healing in infected nonunions 
within four to five months.23 the drawback presented 
with autograft is that it needs additional surgery to collect 
the graft. allograft often presents a large variability in 
bone quality, and the antibiotic loading and dosing var-
ies with loading technique and the antibiotic used.
injections of aqueous solutions as a carrier for antibiot-
ics may be effective in treatment of areas close to articula-
tions26 but the sustained antibiotic level is poor, making it 
inefficient in any application other than as prophylaxis of 
surgical site infections.5
there is a great need for better, more efficient and 
more predictable delivery systems for successful local 
antibiotic delivery, especially in view of the emerging 
development of bacterial resistance worldwide. the main 
aim of this study was to investigate a new commercially 
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available bone substitute that elutes antibiotics, combin-
ing an initial high local release with a sustainable antibi-
otic level for a sufficiently long time to effectively prevent 
infection (ceRameNt G, BoNeSuppoRt aB, lund, 
Sweden). the product was developed by adding antibi-
otics to a clinically well documented bone-regenerating 
biphasic ceramic bone graft substitute.27-30 it is hypothe-
sised that adequate antibiotic release may be achieved, as 
well as new bone ingrowth, to manage the dead space 
created during bone debridement. the gentamicin will 
prevent colonisation of gentamicin-sensitive organisms 
in order to protect bone healing.
the second aim with this study was to compare the 
in vitro and the in vivo elution rate to identify a test method 
that is able to predict the local antibiotic release pattern 
in vivo and thereby make the development of new antibi-
otic delivery systems more effective in the future.
Materials and Methods
Gentamicin release was measured from a synthetic bone 
graft substitute (ceRameNt G) consisting of 40 wt% 
hydroxyapatite particles in a calcium sulphate matrix. 
the bone graft substitute contained 175 mg gentamicin 
per 10 ml.
Gentamicin release was measured in four setups: 
in vitro elution in Ringer’s solution; local elution in patients 
treated for trochanteric hip fractures or uncemented hip 
revisions; local elution in patients treated with a bone 
tumour resection; and local elution in patients treated 
surgically for chronic corticomedullary osteomyelitis.
each study was approved by the local independent 
ethics committee and informed consent was obtained 
from all patients.
In vitro elution in Ringer’s solution. For elution in Ringer’s 
solution, the material was studied either as paste or as 
pre-set beads with high or low surface areas,31 >100 cm2 
and 24 cm2, respectively. the material was prepared 
according to the instructions for use, each sample con-
sisting of 10 ml material. the samples were prepared 
in triplicate and immersed in 200 ml polypropylene 
beakers with 50 ml Ringer’s solution. the pre-set beads 
were allowed to cure before immersion, while the paste 
hardened in the solution. the samples were kept at 
37 °c in an incubator.
the amount of Ringer’s solution used (50 ml) was cal-
culated from the assumption that in an in vivo condition 
the minimal inhibitory concentration (mic) levels for 
pseudomonas and other gentamicin-sensitive micro-
organisms (4 mg/l)32 should be reached in all of the tissue 
surrounding the device up to a distance of approximately 
1 cm (see Fig. 1). it should be noted that therapeutically 
much higher concentrations are needed to reach bacteri-
cidal effect, e.g. four to eight times the mic.33
Since the volume of the implant is 10 ml, the sur-
rounding volume of a distance up to 1.09 cm is approxi-
mately 50 ml according to vsurrounding = vtotal – vimplant = 
4/3 * π(1.34 + 1.09)3 – 10 = 60 -10 = 50 ml.
Samples were taken every 24 hours ± 2 for eight days, 
then once a week for four weeks. Samples of 10 ml (or 
20%) of the solution were exchanged for fresh Ringer’s 
solution in order to simulate the situation in vivo where 
both a liquid/tissue flow and diffusion of gentamicin 
from the tissue surrounding the implant will take place. 
the gentamicin concentration in the samples was ana-
lysed by cloned enzyme donor immunoassay (cedia) on 
Roche cobas, c501 (Roche diagnostics, Risch-Rotkreuz, 
Switzerland).
Before the weekly collections, there was an exchange 
of the solution according to: 
Liquid to replace mL= ⋅ −50 1 0 8( . )n
where n is the number of times the liquid should have 
been replaced if it was still replaced daily. thereafter, the 
sample outtake and replacement were made as before 
(10 ml).
the pH of the liquid surrounding the ceRameNt G 
samples was measured using a pH meter (inolab pH 
level 2p, WtW GmbH, Weilheim, Germany) at each sam-
pling occasion to ensure a stable and physiological pH 
value needed to maintain the activity of the pH-sensitive 
gentamicin.34-37
Local elution in patients treated for trochanteric hip frac-
tures or uncemented hip revisions. a total of 11 patients 
underwent bone augmentation with ceRameNt G during 
1 cm
Tissue
CERAMENT  G
Fig. 1
illustration of the local release model used for the in vitro release test. in an 
in vivo condition the minimal inhibitory concentration levels for gentamicin-
sensitive microorganisms should be reached in all the tissue surrounding 
the device up to a distance of approximately 1 cm. Since the volume of the 
implant is 10 ml, the surrounding volume of a distance up to 1.09 cm is 
approximately 50 ml.
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the surgical management of a trochanteric fracture with 
internal fixation (six patients) and uncemented hip revi-
sion (five patients).the aim was to prevent infections, and 
the hypothesis was that the local concentration of genta-
micin would reach bactericidal level, while the systemic 
concentration would be kept below toxic levels.
the 11 patients (two men, nine women) with a mean 
age of 75 years, (62 to 90; standard deviation (sd) 10) 
underwent the surgery. a mean of 7.3 ml of ceRameNt 
G was implanted (5 to 9; sd 1.1). a rigorous analysis of 
the antibiotic release followed: intra-articular drainage, 
from passive, open drain procedure placed close to the 
surgical site, was assessed at six, 12, 24, 30 and 36 hours 
post-operatively; urine was collected daily during the 
hospital stay (seven days); and blood serum assessed 
every hour for the first six hours post-operatively and 
every six hours (sd 1) thereafter, up to 96 hours post-
operatively (21 samples per patient in total).
the total volume of the drainage was measured for 
each time point. a maximum of 10 ml drainage was col-
lected for each sample and centrifuged for ten minutes at 
2200 × g or 4000 rpm at room temperature. the super-
natant was then separated from the rest and deep frozen 
at -80°c prior to analysis.
the urine was sampled daily from a urinary catheter 
for the first four days and thereafter morning urine was 
collected. the samples were homogenised, transferred 
into two 50 ml tubes and kept cool in a refrigerator.
a minimum of 4 ml of blood was withdrawn at each 
time point and placed in a 5 ml heparin tube. Blood sam-
ples were centrifuged for ten minutes at 2200 × g and the 
supernatant was transferred to two 5 ml polypropylene 
tubes and deep frozen at -80°c until analysis.
None of the patients were prescribed systemic gen-
tamicin during the study period. Gentamicin concentra-
tions were analysed using a validated antibody technique 
(QmS Gentamicin assay, indiko thermo Scientific, 
thermo Fisher Scientific, Waltham, massachusetts).
Local elution in patients treated with a bone tumour resec-
tion. a total of eight patients (five men, three women) 
with a mean age of 54 years (37 to 79; sd 14) underwent 
bone defect reconstruction with the use of a temporary 
drain. a mean of 12.1 ml of ceRameNt G was implanted 
(4 to 20; sd 5.5) and both drainage and blood serum 
were collected daily until two days post-operatively. 
indications for surgery were metastatic bone disease (n = 
3, proximal humerus), giant cell tumour (n = 2, distal 
femur) and chondroid tumour (n = 3, distal femur, proxi-
mal femur, pelvis). additional endoprosthetic recon-
struction with a tumour prosthesis was performed in two 
patients (two proximal humerus). drainage and blood 
were collected immediately post-operatively and on each 
post-operative day until the drain was removed. in two 
cases it was not possible to collect drainage directly post-
operatively due to minimal fluid production. None of the 
patients were prescribed systemic gentamicin during the 
study period. Gentamicin concentrations were analysed 
using a validated antibody technique (QmS Gentamicin 
assay, indiko thermo Scientific).
Local elution in patients treated surgically for chronic 
 corticomedullary osteomyelitis. a total of 13 patients 
(seven men, six women) with a mean age of 47 years (2 
to 65; sd 12) with cierny-mader stage iii and iv chronic 
osteomyelitis38 were treated by resecting the affected 
areas and filling the dead space with a mean of 10.6 ml 
of ceRameNt G (2 to 20; sd 6). Blood serum was col-
lected on the morning after surgery, on day two and on 
day five post-operatively. all operations were performed 
by two surgeons. at the time of osteomyelitis excision 
surgery, tissue samples were collected and cultured to 
identify the causative bacteria. None of the patients were 
prescribed systemic gentamicin during the study period.
Results
In vitro elution in Ringer’s solution. in the elution study 
in vitro, there was a high initial peak in the gentamicin 
concentration for all the samples, with a maintained level 
above 4 mg/l during the whole test period of 28 days, 
which is the mic breakpoint for most gentamicin- sensitive 
microorganisms (Figs 2a and 2b). the maximum gentami-
cin concentration for pre-set beads with high surface area 
was (mean and sd 2879 mg/l; sd 105) obtained on the 
first day (Fig. 2a). For the pre-set beads with low surface 
area and for the paste, the maximum gentamicin concen-
tration was 2420 mg/l (sd 45) and 2354 mg/l (sd 100), 
respectively, obtained on the second day (Fig. 2a). the 
gentamicin concentrations at day 28 were 43 mg/l; sd 8 
for the high surface samples, 43 mg/l; sd 11 for the low 
surface samples and 65 mg/l; sd 8 for the paste (Fig. 2b). 
all gentamicin was released during the test period and 
more than 95% had been released after two to four days 
independently of the surface area of the material, or 
whether it was pre-set or paste.
the pH in the liquid surrounding the samples was a 
mean of 7.00 (sd 0.13) during the 28 days of measure-
ments, assuring good activity and predictability of the 
gentamicin against Staphylococcus aureus, Escherichia coli 
and Salmonella entericae.34-37
Local elution in patients treated for trochanteric hip frac-
tures, uncemented hip revisions and after bone tumour 
resection. in the clinical studies similar results were 
found, with high initial levels of gentamicin detected in 
the drainage, followed by a decreasing concentration 
(Fig. 3). Gentamicin was detected in the serum in most 
patients during the first post-operative days, although 
always well below the maximum recommended systemic 
level of 10 mg/l (Fig. 4). it was even less than 2 mg/l, to 
which the serum concentration should decline between 
doses to avoid toxicity during systemic administration. 
Gentamicin concentrations in both drainage and serum 
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were higher in the bone tumour patients, which prob-
ably reflects the larger volume of ceRameNt G used. 
Gentamicin was detected in urine during the first post-
operative week (Fig. 5).
Local elution in patients treated surgically for chronic cor-
ticomedullary osteomyelitis. the gentamicin levels in the 
serum of the patients treated for chronic osteomyelitis 
were low. in all, eight of the 13 patients had gentamicin 
concentrations of less than 0.2 mg/l on the day after sur-
gery and the levels were maintained over the first five days 
post-operatively or for as long as samples were collected. 
the other five patients had slightly higher gentamicin 
concentrations in the serum the day after operation, at 
a mean of 0.54 mg/l (sd 0.43), however, thereafter the 
levels were as low as for the rest of the patient group. No 
patient had levels which would be associated with any 
systemic toxicity.
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Fig. 2
Graphs showing a) gentamicin concentration over time in Ringer’s solution, no difference was observed between pre-set beads with high and low surface area 
and paste; and b) on log scale over time: same results as in Fig 2a, clearly showing levels over 4 mg/l, which is the minimal inhibitory concentration break point 
for most gentamicin-sensitive microorganisms. line = mean values.
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Fig. 3
Graph showing gentamicing concentrations in wound drainage from patients 
undergoing tumour surgery or hip surgery. High initial local concentrations of 
gentamicin were observed (100 times minimal inhibitory concentration (mic) 
at six hours and still ten times the mic at 30 hours), with a rapid decrease dur-
ing the following days. line = mean values.
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Fig. 4
Graph showing detectable levels of gentamicin in serum from tumour and hip 
patients for the first two days post-operatively. the local levels of gentamicin 
are generally 1000 times higher than systemic levels. line = mean values.
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Fig. 5
Graph showing detectable gentamicin concentrations in urine from hip sur-
gery patients for seven days post-operatively. these levels are about ten times 
higher than the systemic concentrations measured in serum, indicating bacte-
ricidal local levels in the region of surgery. line = mean values.
432 M. StravinSkaS, P. HorStMann, J. FerguSon, W. HettWer, M. nilSSon, S. taraSeviciuS, M. M. PeterSen, M. a. Mcnally, l. lidgren
Bone & Joint reSearcH
a breakdown of the organisms cultured at the time of 
osteomyelitis excision surgery is outlined in table i. there 
were four cases with no growth, probably due to long-
term antibiotic treatment and multiple recurrences of the 
osteomyelitis. of the remaining nine cases with positive 
cultures, eight were monomicrobial and the final was 
polymicrobial. Five cases cultured gentamicin-sensitive 
organisms, as defined by the european committee on 
antimicrobial Susceptibility testing (eucaSt) break-
points for resistance.
the remaining four cases demonstrated some degree 
of gentamicin resistance, with one case showing interme-
diate resistance and the remaining three being fully gen-
tamicin-resistant organisms.
No recurrence had been detected for any of the 
patients for the minimum follow-up time of 1.5 years.
Discussion
the initial gentamicin release in vitro from the synthetic 
bone graft substitute was similar to that observed in the 
three different clinical applications. When comparing the 
elution in Ringer’s solution with gentamicin concentra-
tions in the drainage from both the hip and the tumour 
patients, a high local antibiotic concentration was 
observed. it decreased with time, slightly faster for the 
in vivo studies with a half-life of two days for the tumour 
patients and 0.5 days for the hip patients, compared with 
five to six days for the in vitro study. these differences in 
half-life may be explained by the differences of measure-
ments and collection of samples. in the elution study, the 
gentamicin concentration is measured within 1 cm of the 
implant, which gives a truly local concentration. the 
in vivo studies show the concentration of gentamicin in 
the drainage which may be considered further away from 
the implant than 1 cm, giving slightly inferior values of 
the gentamicin concentration compared with the in vitro 
study. the static incubation with controlled exchange of 
20% of the liquid in the in vitro study may be slower than 
the actual exchange, which would explain the shorter 
half-life in the in vivo studies. also, dissolution of the 
calcium sulphate component of the bone graft substitute 
occurs in vitro compared with both dissolution and cel-
lular resorption in vivo, possibly speeding up the release.
the trend is still clear, with an elution pattern that 
starts with a burst which decreases with time and is main-
tained above the mic level for four weeks. the gen-
tamicin release pattern observed thus confirms that the 
in vitro release model used was found to simulate the per-
formance in clinical applications, which was one of the 
aims of this study. Having a reliable in vitro model will 
impact the research and development of new drug-
releasing compounds significantly since in vitro tests are 
much more time- and cost-efficient than expensive ani-
mal trials.
the local antibiotic concentrations in both the hip and 
the tumour study were 100 times the mic at six hours 
and still ten times the mic at 30 hours. this should allow 
eradication of any planktonic bacteria causing infection 
and give good preventative levels. the total amount of 
gentamicin-containing bone substitute implanted in the 
tumour patients was higher than that used for the hip 
patients (mean 12.1 ml versus 7.3 ml) which may explain 
why the gentamicin concentrations in the tumour 
patients were higher.
it is important that the initial release is significantly 
above the mic level locally to prevent bacterial adherence 
leading to an established deep infection.39 even though no 
data on local levels of gentamicin were collected from the 
clinical study in osteomyelitis patients, there was no recur-
rence of the infection in any of these patients for the entire 
1.5 years’ follow-up time, indicating that the local levels 
were indeed high enough to eradicate the majority of bac-
teria. this has further been confirmed in a larger series of 
clinical cases with a very low rate of recurrence of osteo-
myelitis.40 the bacterial cultures from the time of osteomy-
elitis excision surgery showed three cases of resistant 
bacteria as defined by eucaSt: methicillin-resistant staph-
ylococcus aureus, Streptococcus agalactiae and Clostridium 
difficile. However, the test methods used to define the 
resistance do not necessarily apply here since they are 
designed for treatment of non-biofilm bacteria and sys-
temic therapy. the local gentamicin concentration during 
elution from the bone substitute material reaches 100 to 
1000 times the mic level and may therefore be effective in 
preventing recurrence by eradicating gentamicin-resist-
ant bacteria.
a detectable gentamicin concentration in urine 
observed for up to seven days in the hip patients indi-
cates prolonged drug release in these cases.
the initial release pattern of antibiotics in this study, 
using a resorbable bone substitute, is comparable with 
that of gentamicin-containing pmma beads,41 with high 
initial antibiotic levels followed by slower release. in 
Hedström’s study, 41 the peak release of gentamicin was 
around ten times the mic but others have reported initial 
Table I. the cultures of osteomyelitis causative bacteria showed four cases 
with no growth, eight cases were monomicrobial and one case was polymi-
crobial. Five cases cultured gentamicin-sensitive organisms and four cases 
demonstrated some degree of gentamicin resistance
Organism Patients (n) Gentamicin 
resistance
No growth 4  
Staphylococcus aureus 2 Sensitive
methicillin-resistant staphylococcus aureus 1 Resistant
Streptococcus agalactiae 1 Resistant
Enterobacter cloacae 1 Sensitive
Salmonella enteritidis 1 intermediate
Clostridium difficile 1 Resistant
Corynebacterium spp. 1 Sensitive
mixed Growth (Staphylococcus aureus and 
Enterobacter cloacae)
1 Sensitive
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release from pmma beads as high as 100 times the mic 
value which is known to be effective.14 ideally, the high 
local antibiotic concentration of 100 times the mic 
should last for the first one to two days and thereafter a 
prolonged release at a level closer to the mic should be 
maintained for another four weeks.42,43 Since pmma 
only releases the antibiotics from the surface by diffu-
sion, most of the gentamicin remains trapped in the 
pmma matrix, resulting in a prolonged release at antibi-
otic concentrations below the therapeutic level. 
Walenkamp44 calculated that approximately 24% (sd 
11%) of the total gentamicin amount was released from 
the pmma beads over 14 days, compared with 95% for 
the ceramic bone substitute used in this study. prolonged 
antibiotic release at low levels may induce antibiotic 
resistance.45 in 1989, Hope et al46 found that 90% of 
Staphylococcal strains isolated from infected hip replace-
ments were resistant to gentamicin after using gen-
tamicin-containing pmma cement, compared with 16% 
if plain cement had been used. other studies have con-
firmed that antibiotic-loaded pmma cement reduces 
infection in total joint arthroplasty at the cost of increas-
ing case-specific resistance.4,47 the studied bone graft 
substitute is porous, allowing elution from the bulk 
(without surface dependency) and avoiding antibiotics 
getting trapped in the material. in this study, it was con-
sidered that 100% of the antibiotics had been eluted at 
28 days. moreover, the bone graft substitute is biode-
gradable30 and will be resorbed by the body over a 
period of approximately two years27 depending on the 
amount used and the implant site.
the most severe side effects following the use of sys-
temic gentamicin are renal failure and ototoxicity. these 
complications are known to occur at high systemic levels 
of gentamicin but may also result with prolonged gen-
tamicin release, especially if the patient is already suffer-
ing from renal insufficiency.48 it is therefore important to 
use a carrier which assures complete release of the gen-
tamicin within a short period of time to avoid the risk of 
prolonged and non-reversible exposure to the antibiotic.
Fleiter et al49 treated 20 patients with osteomyelitis (11 
in tibia, seven in femur, one humeral head and one meta-
tarsal bone) using local implantation of a calcium sul-
phate/carbonate bone void filler containing gentamicin. 
collection of drainage, serum and urine showed similar 
gentamicin release curves to those obtained in this study. 
For all cases, an initial burst was observed followed by a 
decrease in gentamicin release over the next few days. 
the gentamicin concentrations were generally lower in 
the osteomyelitis patients studied by Fleiter et al49 than in 
the hip and tumour patients studied herein. these results 
correlate well with ours, where the highest gentamicin 
concentration measured in serum was 0.54 mg/l (at one 
day post-operatively) in the osteomyelitis patients, com-
pared with 0.6 mg/l in Fleiter et al’s study. the mean 
gentamicin amount implanted by Fleiter et al49 was 187 
mg versus 186 mg in the current study.
due to a limitation in the analysis instrument used in 
our in vivo studies, where the minimal detectable gen-
tamicin concentration was 0.2 mg/l, no release curves 
could be obtained for the osteomyelitis patients. 
However, comparing the results from the osteomyelitis 
patients studied by Fleiter et al49 with our hip and tumour 
patients, it is most probable that the release curves for the 
osteomyelitis patients in our study follow the same 
pattern.
Fleiter et al49 reported recurrent infections in one fifth 
of the study group (four patients) several weeks to 
months after surgery, and indicate antibiotic resistance as 
one possible cause due to repeated local treatment with 
gentamicin. in our study, no recurrence had been identi-
fied 1.5 years after implantation. Fleiter et al49 concluded 
that local treatment with a resorbable gentamicin-con-
taining bone void filler is a useful option in the battle 
against deep bone infection. the potential for systemic 
side effects are minimal with local treatment, and subse-
quent procedures to remove implanted material and fill-
ing of the dead space are avoided by the use of a 
resorbable bone-regenerating carrier.
our study highlights four important aspects regarding 
the elution of gentamicin from this ceramic synthetic 
bone graft substitute, which makes the use more predict-
able compared with other carriers: gentamicin is homog-
enously distributed in the bone substitute ensuring an 
even release; the elution of the antibiotic is not surface 
dependent, i.e. antibiotic release occurs from the mate-
rial bulk as well as from the surface of the sample; the 
release occurs in the same way from pre-set beads or 
injectable in situ setting paste, making it effective irre-
spective of how it is applied; and all gentamicin added to 
the bone substitute will be eluted. the antibiotic will 
accumulate in the surrounding tissue of the defect and be 
locally present in levels above the mic for the ensuing 
weeks, depending on the degree of vascularisation of the 
area and the degree of wound drainage.15
Results from cell cultures in vitro suggest that gen-
tamicin might have a negative impact on the osteoblast, 
indicating a time-dependent impact on cell number/prolif-
eration and a dose-dependent impact on protein synthesis 
and cell viability, although there is not a consensus in the 
results of the studies.50-55 However, animal and human 
in vivo data show no impact on the bone repair process, 
and even show a protective effect when a local bone infec-
tion exists.56-58 this has been confirmed in animal studies 
with ceRameNt G, showing active remodelling into bone 
despite the high initial gentamicin release.31,59
dvorzhinskiy et al59 studied ceRameNt G versus 
ceRameNt BoNe void FilleR without antibiotics in a rat 
osteomyelitis model. empty voids were held as controls. 
Six weeks after debridement and implantation, the 
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ceRameNt G group showed no infections versus 30% 
positive cultures in the ceRameNt BoNe void FilleR 
group and 25% in the control group (p < 0.05). the bone 
volume/total volume ratio of the region of interest in the 
ceRameNt G group was 24% greater than in the 
ceRameNt BoNe void FilleR group and 94% greater 
than in the control group (p < 0.05). the study also 
showed that once the infection had cleared the bone 
regenerated better and faster.
the ceramic bone substitute used in this study con-
tains gentamicin, providing an efficient antibiotic release 
and ensuring bone remodeling at the site of debride-
ment. the advantage of using a resorbable bone substi-
tute over pmma is that a one-step treatment can be 
performed, both preventing the reinfection by local anti-
biotic release and promoting new bone ingrowth with-
out the removal of the bone substitute, as is the case with 
acrylic cement carriers. a second surgery to manage the 
bone void is avoided and a faster bone healing process is 
achieved.
in conclusion, this novel antibiotic-eluting biphasic 
ceramic bone substitute shows promise as one of the 
steps in the management of chronic osteomyelitis, the 
prevention of infection and the healing of bone defects in 
a safe and effective way. a reliable in vitro test method 
that predicts in vivo performance has been identified for 
future development of additional new antibiotic-eluting 
bone regenerating materials.
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